Technology | Guidewires | February 19, 2016

Nipro Medical Corp. Launches AquaLiner II Nitinol Guidewire in the U.S.

Hydrophilic, super-elastic second-generation guidewire provides control needed to navigate complex lesions

February 19, 2016 — Nipro North America announced the launch of the AquaLiner II second-generation 0.035-inch, hydrophilic, super-elastic nitinol guidewire. The guidewire enables the operator to navigate through complex lesions and deliver interventional devices such as balloons and stents.

AquaLiner II's improved, kink-resistant nitinol core provides the control needed to navigate the vasculature by absorbing strain and maintaining strength. The super-elasticity of the device’s core wire conforms to the patient's vasculature and provides excellent support for interventional devices.

The guidewire's hydrophilic coating delivers the durability required to maintain lubricity throughout the procedure even through multiple passes. AquaLiner II also delivers ienhanced tactile feel, pushability and trackability, even in the most challenging anatomy.

The chemically-engineered tip delivers a smooth, atraumatic insertion and navigation through vessels. Minimal force is required, allowing for better steerability and control. The tapered tip also provides optimal stability, while still maintaining a flexible soft taper.

AquaLiner II is available in various lengths, ranging from 150cm to 260cm, with a regular or stiff-configured wire and with a straight or angled tip.

For more information:

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init